Member Info for Microcap1

This theoretical limit of 70/75p and cycle of sell-downs into good results its really a feature of the board's reluctance to market the stock with amplification - it was a sensible thing to do following the bail-out placing 4 years ago and the Company's turn around but that has now happened and the stock needs to be re-marketed.

I also cannot see the benefit of Cavendish (formerly FinnCap) as the Company's broker, they're only motivated to market those stocks where there's an upcoming placing to make fees. TRX doesn't need money. It's time the Board look to a Jeffries or back to a Stifel, brokers with seriously deep US healthcare investor contact suites who can now market TRX as a US based EBITDA positive niche provider of surgical product that is trading on a comparatively cheap multiple. This would likely see new institutional investment and quite possibly a larger suitor within distribution that would take aim at making an offer for the Company.

So "Gregmn" just to be clear, you've speculatively posted that the stock price is falling on the boards of ECO, EST, CWR, HE1, CPX and QBT. The difference you might find with ECO is that it enjoys an investor base that are longer term in horizon and will patiently wait to capture multiple scheduled commercial events that are driven by energy majors. The Company will also be in receipt of material payments from globally recognised energy companies which are scheduled regardless of success/unsuccessful drills. Not the most intelligent shorting play but looking at your posts wisdom isn't the first word that comes to mind, nice try.

"Copper price to rocket to $40,000 a tonne, says top trader Andurand" https://www.ft.com/content/725234a6-9e6f-4a4a-9406-2bda667ca511

Galp Energia (15bn EUR market cap) had the following glowing endorsement of their Namibia asset (located next to Eco's) in their Q1 results this morning from their CEO Filipe Silva:

"In Namibia, together with our two local partners Namcor and Custos, we have significantly de-risked the Mopane complex after completing the first two wells and the DST in Mopane 1X. We have encountered significant light oil columns in high quality reservoir conditions, placing Mopane as a potential major commercial discovery. This should support the growth profile of Galp for the next decades to come, as we gradually lower the carbon intensity of our downstream businesses.”

The current sp, which I don't think anyone disagrees is very depressed, is a feature of a fear that the Company will need to do a fundraising in order to extend their Q2 '25 cash runway to get to cash flow break-even.

Investors in other healthcare stocks have been burned before by deeply discounted placings and recently there's been a number or listing cancellations from peers of ANGLE that ran out of money including the likes or RedX, ReNeuron etc

On a factual basis this isn't a like-for-like situation, why, well quite simply:

Who were the advisors/brokers on those other stocks? Small-cap commission driven houses. ANGLE has a grown up Mid-Cap broker

How many of those stocks had contracts with AstraZeneca? None

ANGLE were at 30p+ in Jan, they could have raised money then with ease if they wanted to, they didn't. So clearly they have plenty of optionality and are not panicking

They are now in-play with both EISAI and AstraZeneca where the end demand for their $1000+ kits which are required 2 or 3 times per patient will be needed for 10's of thousands of patients (do the maths)

The Company could walk into a top-tier finance house today with the credentials of EISAI and AstraZeneca and get a Rolling Credit Facility if they really wanted to, they don't have to come to equity markets if they feel their valuation isn't being truly reflected

So whilst investors are referring to the pain of previous experiences it really isn't relevant here

Finally I think its very sad that a small British quoted company like ANGLE which has an FDA approved cancer detection product being put to use by 2 global Pharma companies has people shunning it for its cash position as if it were some pie in the sky early stage niche drug development company

One can only assume that if this trial is successful it will open ANGLE up to the full AstraZeneca pipeline which is 10's of thousands of patients needing multiple ANGLE test kits...the revenue could be company making!!

Also a big sign of confidence that Astra allowed their name to be used in the RNS they're usually very discreet so it shows confidence that they're happy to be associated with ANGLE. This is incredible news!!

Congratulations to Management on their consistency. Once again they have apparently got close before announcing another perpetual delay. In the spirit of that consistency time to cue the forthcoming heavily discounted placing to keep Management's high salaries intact so they can continue with their track record of never delivering. Bravo!

German energy giant Uniper SE has announced it will restart a hard-fired coal power plant to produce electricity for the market as Berlin races to secure energy for winter. The first of many European cities to do the same? Coal switch starting to look more relevant than ever!